CoChat

Temporal Dynamics of β-Amyloid Accumulation in Aging and Alzheimer Disease

Open access
Jagust, William J., Landau, Susan M., for the Alzheimer's Disease Neuroimaging Initiative Michael W. Weiner MD Paul Aisen MD Michael Weiner MD Paul Aisen MD Ronald Petersen MD, PhD Clifford R. Jack Jr. MD William Jagust MD John Q. Trojanowki MD, PhD Arthur W. Toga PhD Laurel Beckett PhD Robert C. Green MD, MPH Andrew J. Saykin PsyD John Morris MD Leslie M. Shaw Zaven Khachaturian PhD Greg Sorensen MD Maria Carrillo PhD Lew Kuller MD Marc Raichle MD Steven Paul MD Peter Davies MD Howard Fillit MD Franz Hefti PhD David Holtzman MD M. Marcel Mesu · 2021 · Neurology
Cited by 122

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Objective To understand the time course of β-amyloid (Aβ) deposition in the brain, which is crucial for planning therapeutic trials of Aβ-lowering therapies in Alzheimer disease (AD). Methods Two samples of participants from the Alzheimer9s Disease Neuroimaging Initiative were studied with [18F]Florbetapir (FBP) Aβ PET and followed for up to 9 years. Sample A included 475 cognitively normal (CN) older people and those with mild cognitive impairment (MCI) and AD and sample B included 220 CN Aβ− individuals. We examined the trajectory of FBP over time in sample A and the incidence rate of conversion from negative to positive Aβ PET scans in sample B. Results The relationship between time and brain Aβ was sigmoidal, taking 6.4 years to transition from amyloid negative to positive and another 13.9 years to the onset of MCI. Aβ deposition rates began to slow only 3.8 years after reaching the positivity threshold. The incidence rate for scan positivity was 38/1,000 person-years, and factors associated with conversion were age, baseline FBP, and being a female APOE ε4 carrier. Among CN Aβ− individuals, FBP slopes were associated with rates of memory decline and brain tau measured with [18F]Flortaucipir PET 5 years after baseline. Conclusions Lowering brain Aβ must be accomplished early in the evolution of AD. Transitions of PET scans from Aβ− to Aβ+ should be predictable, and it is reasonable to expect that lowering rates of Aβ even in early stages could produce clinically significant benefits.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0000000000011524

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 122

Metadata

Authors
Jagust, W. J., Landau, S. M., & for the Alzheimer's Disease Neuroimaging Initiative Michael W. Weiner MD Paul Aisen MD Michael Weiner MD Paul Aisen MD Ronald Petersen MD, P. C. R. J. J. M. W. J. M. J. Q. T. M.
Venue
Neurology
Published
2021-03-02
Volume
96
Issue
9
Pages
e1347-e1357
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W3118496727
Cited by
122
References
16
FWCI
11.58
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Temporal Dynamics of β-Amyloid Accumulation in Aging and Alzheimer Disease. https://app.cochat.ai/papers/10.1212/wnl.0000000000011524
The paper
Jagust, W. J., Landau, S. M., & for the Alzheimer's Disease Neuroimaging Initiative Michael W. Weiner MD Paul Aisen MD Michael Weiner MD Paul Aisen MD Ronald Petersen MD, P. C. R. J. J. M. W. J. M. J. Q. T. M. (2021). Temporal Dynamics of β-Amyloid Accumulation in Aging and Alzheimer Disease. Neurology. https://doi.org/10.1212/wnl.0000000000011524

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.